Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial

Table 2 Main outcomes

	Group A (n = 110)	Group B (n = 110)	P-value	Risk ratio (95% CI)
Need for IMV	38/107 (35.5%)	43/106 (40.6%)	0.448	0.874 (0.685–1.18)
Duration of O2 support^#	7 (5–12)	8 (6–15.75)	0.098
AKI	9 (8.3%)	13 (11.8%)	0.381	0.7 (0.57–1.21)
In hospital mortality	45 (40.9%)	49 (44.5%)	0.586	0.919 (0.713–1.21)
28-day mortality	52/104 (50%)	54/103 (52.4%)	0.727	0.95 (0.731–1.244)
Six-month mortality	53/102 (52%)	59/97 (60.8%)	0.208	0.854 (0.668–1.092)

Data presented as mean (SD), median (P_25th–P_75th), or number (%)
Group A: Atorvastatin group; Group B: Placebo group; IMV: Invasive Mechanical Ventilation; ICU: Intensive Care Unit; AKI: Acute Kidney Injury; 95% CI: 95% Confidence Interval
^*P ≤ 0.05 indicated statistical significance
^#In survived patients till discharge, Data is analyzed based on available case analysis

ISSN: 1465-993X